Faget Quoted in MedTech Dive on the FDA’s Response to the COVID Crisis
March 15, 2021
MedTech Dive
Kyle Faget, partner and member of the firm’s Health Care and Life Sciences Industry Team, was quoted in a MedTech Dive article titled, “5 Things Medtech Can Expect from FDA in 2021.”
Faget told MedTech Dive that she sees the FDA in 2021 releasing its long-awaited publication of the revised Quality System Regulation. She also stated that: “What we saw a lot of in the Trump administration was HHS getting very involved in FDA’s business and we’re going to see less of that.” She continued, “There’s going to be much more deference to FDA as an independent regulatory body.”
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“